V. Caglayan, “Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl”, Arch Ital Urol Androl, vol. 90, no. 4, pp. 270–275, Jan. 2019.